Expression of CD44, PCNA and E-cadherin in Pterygium Tissue

Sponsor
Balikesir University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06042296
Collaborator
(none)
60
1
3
19.9

Study Details

Study Description

Brief Summary

Purpose: Pterygium is a common ocular surface disease defined by fibrovascular conjunctival growth extending onto the cornea. Its pathogenesis remains unclear. In severe cases, it may extend into the central cornea, inducing irregular corneal astigmatism and causing loss of vision. CD44( phagocytic glycoprotein-1 ) is involved in the organization of certain cellular processes, for instance, cell adhesion, division, and migration, by binding with its main ligand, hyaluronic acid. Proliferating cell nuclear antigen (PCNA) is a proliferation marker in the nucleus. E-cadherin is a calcium-dependent transmembrane glycoprotein that plays a significant role in the protection of tissue integrity and cell-to-cell adhesion. This study aimed to determine the role of CD44, proliferating cell nuclear antigen (PCNA), and E-cadherin in pterygium formation and recurrence.

Condition or Disease Intervention/Treatment Phase
  • Other: Expression of CD44, E-cadherin and PCNA

Detailed Description

Methods:60 patients with pterygium will be enrolled in the study and conjunctival samples will be collected from 30 patients to form the control group. CD44, PCNA and E-cadherin expressions in surgically removed pterygium will be compared with tissue samples from normal control group.

IBM SPSS (statistical software) version 26.0 will be used for statistical analyses.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
60 participants
Observational Model:
Case-Control
Time Perspective:
Cross-Sectional
Official Title:
Expression of CD44, PCNA and E-cadherin in Pterygium Tissue
Anticipated Study Start Date :
Oct 1, 2023
Anticipated Primary Completion Date :
Dec 1, 2023
Anticipated Study Completion Date :
Jan 1, 2024

Arms and Interventions

Arm Intervention/Treatment
control group

group 1 -control group normal conjunctiva from 30 patients

Other: Expression of CD44, E-cadherin and PCNA
The investigators use primary antibodies against CD44 (1:50 dilution) and E-cadherin (1:200 dilution), and a human monoclonal antibody against PCNA (1:100 dilution) for antigen retrieval. Histopathological and immunohistochemical staining findings will be reported using a Nikon light microscope and an image analysis system (Nikon Instruments Europe BV)

group 2 primary pterygia

primary pterygia samples from 30 patients

Other: Expression of CD44, E-cadherin and PCNA
The investigators use primary antibodies against CD44 (1:50 dilution) and E-cadherin (1:200 dilution), and a human monoclonal antibody against PCNA (1:100 dilution) for antigen retrieval. Histopathological and immunohistochemical staining findings will be reported using a Nikon light microscope and an image analysis system (Nikon Instruments Europe BV)

group 3 recurrent pterygia

recurrent pterygia samples from 30 patients

Other: Expression of CD44, E-cadherin and PCNA
The investigators use primary antibodies against CD44 (1:50 dilution) and E-cadherin (1:200 dilution), and a human monoclonal antibody against PCNA (1:100 dilution) for antigen retrieval. Histopathological and immunohistochemical staining findings will be reported using a Nikon light microscope and an image analysis system (Nikon Instruments Europe BV)

Outcome Measures

Primary Outcome Measures

  1. Immunohistochemistry [up to three weeks after pterygium surgery]

    Thin sections will be taken from paraffin embedded tissue samples and placed on barcode glass slides After deparaffinization and rehydration, the sections will be subjected to histopathological evaluation using hematoxylin and eosin staining.We use primary antibodies against CD44 (1:50 dilution) and E-cadherin (1:200 dilution), and a human monoclonal antibody against PCNA (1:100 dilution) for antigen retrieval

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No

Inclusion Criteria: patient with pterygium -

Exclusion Criteria: patient with pseudopterygium

-

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hümeyra Yildirim Balıkesir Turkey 10100

Sponsors and Collaborators

  • Balikesir University

Investigators

  • Principal Investigator: HÜMEYRA YILDIRIM, Balıkesir Medical Faculty

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
HUMEYRA YILDIRIM, Expression of CD44, PCNA and E-cadherin in pterygium tissue, Balikesir University
ClinicalTrials.gov Identifier:
NCT06042296
Other Study ID Numbers:
  • BAUNHYILDIRIM-1
First Posted:
Sep 18, 2023
Last Update Posted:
Sep 18, 2023
Last Verified:
Sep 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by HUMEYRA YILDIRIM, Expression of CD44, PCNA and E-cadherin in pterygium tissue, Balikesir University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 18, 2023